MBX Biosciences, Inc.

NasdaqGS:MBX Stock Report

Market Cap: US$3.2b

MBX Biosciences Management

Management criteria checks 1/4

MBX Biosciences' CEO is Steve Hoerter, appointed in Jul 2026, has a tenure of 1.25 years. directly owns 0.067% of the company’s shares, worth $2.12M. The average tenure of the management team and the board of directors is 0.9 years and 2.1 years respectively.

Key information

Steve Hoerter

Chief executive officer

US$1.0m

Total compensation

CEO salary percentagen/a
CEO tenureno data
CEO ownership0.07%
Management average tenureless than a year
Board average tenure2.1yrs

Recent management updates

Recent updates

Seeking Alpha • Jul 06

MBX Biosciences: Weekly PTH, Monthly Obesity, Multi-Year Upside (Initiating Buy)

Summary I initiate MBX Biosciences with a speculative buy, anchored by Canvuparatide's de-risked clinical profile and differentiated dosing convenience. MBXX's Precision Endocrine Peptide platform enables longer-acting, less frequent dosing, addressing key safety and compliance issues in hypoparathyroidism and obesity. Canvuparatide's Phase 2 data show strong efficacy and patient benefit, but Phase 3 must address PK variability and long-term calcium control risks. MBXX's obesity pipeline offers asymmetric upside, while $440M cash extends runway into 2029, mitigating near-term financing risk. Canvuparatide's phase 3 readout comes with risk, similar to recent Eneboparatide failing phase 3 trial (although their ph2 was positive), so we see MBX as a speculative buy. Read the full article on Seeking Alpha
Analysis Article • Jun 17

MBX Biosciences (MBX) Stock Looks Fully Valued After New Phase 2 Data

MBX Biosciences (MBX) has drawn fresh attention after publishing full Phase 2 Avail and one-year open-label data for its lead candidate canvuparatide in chronic hypoparathyroidism, alongside confirming plans for a pivotal Phase 3 trial. See our latest analysis for MBX Biosciences. Against this backdrop, MBX Biosciences stock has seen strong momentum, with a 7 day share price return of 29.36% and a 90 day share price return of 41.01%, while the 1 year total shareholder return is very large at...
Analysis Article • Jun 28

Companies Like MBX Biosciences (NASDAQ:MBX) Are In A Position To Invest In Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Mar 13

We're Not Very Worried About MBX Biosciences' (NASDAQ:MBX) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Nov 14

MBX Biosciences: Decent Potential For Lead Indication, But Need More Data

Summary MBX Biosciences, a recent IPO, develops precision peptide therapies for endocrine and metabolic disorders, with lead asset MBX 2109 in phase 2 for Hypoparathyroidism. MBX 2109, a once-weekly PTH replacement therapy, shows promising phase 1 results with stable drug concentration and potential to improve patient compliance over daily treatments. Financially, MBX has a market cap of $784mn and a cash runway of 12-14 quarters, sufficient to reach phase 2 trial data by Q3 2025. Despite promising prospects, I will wait for phase 2 trial data and pricing information before considering a position, while monitoring Yorvipath's market performance. Read the full article on Seeking Alpha

CEO

Steve Hoerter (55 yo)

no data
Tenure
US$999,986
Compensation

Mr. Steven L. Hoerter, also known as Steve, is Director of Yarrow Bioscience, Inc since July 27, 2026. Mr. Hoerter is President and Chief Executive Officer of MBX Biosciences, Inc. from July 13, 2026. He w...

Leadership Team

NamePositionTenureCompensationOwnership
Steven Hoerter
Executive Chairpersonno dataUS$999.99k0.067%
$ 2.1m
Peter Hawryluk
Executive Officerno dataUS$2.99m2.55%
$ 80.7m
Salomon Azoulay
Chief Medical Officer2.1yrsUS$1.47m0.031%
$ 981.6k
John Smither
Chief Financial Officerless than a yearno datano data
Pete De Spain
Senior Vice President of Investor Relations & Corporate Communicationsless than a yearno datano data
Michelle Graham
Chief Human Resources Officer2.8yrsno datano data
Michael Dorato
Sr. Vice President of Discovery & Non-Clinical Development1.9yrsno datano data
Chatan Charan
Senior VP of Pharmaceutical Development & Chemistry1.3yrsno datano data
Mark Hope
Senior Vice President of Regulatory & Quality1.3yrsno datano data
Andreas Moraitis
Senior Vice President of Clinical Development1.1yrsno datano data
Karen Basbaum
Chief Business Officerless than a yearno datano data
Mark Soued
Chief Commercial Officerless than a yearno datano data
0.9yrs
Average Tenure
59yo
Average Age

Experienced Management: MBX's management team is not considered experienced ( 0.9 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Steven Hoerter
Executive Chairperson1.3yrsUS$999.99k0.067%
$ 2.1m
Patrick Heron
Independent Director6yrsUS$220.95k0%
$ 0
Edward Mathers
Independent Director6yrsUS$196.19k0%
$ 0
Willard Dere
Member of Scientific Advisory Board2.1yrsno datano data
Ora Pescovitz
Independent Director4.3yrsUS$198.95k0.051%
$ 1.6m
Michael Econs
Member of Scientific Advisory Board2.1yrsno datano data
Tiba Aynechi
Independent Director3.7yrsUS$200.69k0%
$ 0
Steven Ryder
Independent Director2.4yrsUS$194.95k0%
$ 0
Laurie Stelzer
Independent Directorless than a yearno datano data
John Bilezikian
Member of Scientific Advisory Boardno datano datano data
Mishaela Rubin
Member of Scientific Advisory Board2.1yrsno datano data
Dolores Shoback
Member of Scientific Advisory Board2.1yrsno datano data
2.1yrs
Average Tenure
62yo
Average Age

Experienced Board: MBX's board of directors are not considered experienced ( 2.1 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/31 12:22
End of Day Share Price 2026/07/31 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

MBX Biosciences, Inc. is covered by 14 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Eliana MerleBarclays
Jonathan WollebenCitizens JMP Securities, LLC
Corinne JohnsonGoldman Sachs